# reload+after+2024-01-21 21:43:33.446682
address1§540 Gaither Road
address2§Suite 400
city§Rockville
state§MD
zip§20850
country§United States
phone§410 522 8707
website§https://www.avalotx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
fullTimeEmployees§20
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Garry A. Neil M.D.', 'age': 69, 'title': 'Chairman of the Board, President & CEO', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 601900, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher Ryan Sullivan', 'age': 39, 'title': 'CFO & Head of Investor relations', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 466935, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Solomon H. Snyder M.D.', 'age': 84, 'title': 'Founder and Chairman of Scientific Advisory Board', 'yearBorn': 1939, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Barbara S. Slusher Ph.D.', 'age': 58, 'title': 'Founder and Member of Scientific Advisory Board', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Lisa  Hegg Ph.D.', 'title': 'Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Colleen  Matkowski', 'title': 'Senior Vice President of Global Regulatory Affairs & Quality Assurance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Dino C. Miano Ph.D.', 'title': 'Senior Vice President of CMC & Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.996
priceToSalesTrailing12Months§3.0367835
currency§USD
dateShortInterest§1702598400
forwardEps§-16.8
exchange§NCM
quoteType§EQUITY
shortName§Avalo Therapeutics, Inc.
longName§Avalo Therapeutics, Inc.
firstTradeDateEpochUtc§1444829400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§c39cf053-89ed-3335-9b81-3e09163c6ebf
gmtOffSetMilliseconds§-18000000
targetHighPrice§0.75
targetLowPrice§0.75
targetMeanPrice§0.75
targetMedianPrice§0.75
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§1.951
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
